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Abstract
Background: Candida albicans is a frequent opportunistic pathogenic 
fungus that causes mucosal and systemic infections. The alcohol dehy-
drogenase 1 (ADH1) and DDR48 genes were found to be upregulated 
in fluconazole resistant Candida albicans. Therefore,   understanding 
the function of drug resistance of genes will help in the development 
of new antifungal agents that can reverse drug resistance. This study 
aimed to investigate the role of ADH1 and DDR48 genes in develop-
ment of fluconazole resistant C. albicans.
Subjects and Methods: This study involved 19 fluconazole susceptible 
and 6 fluconazole resistant C. albicans isolates from clinical specimens. 
The MICs of fluconazole were determined by the E-test. Quantitative 
expressions of Candida Drug Resistance (ADH1, CDR1, DDR48 and 
FLU1) genes were assessed by real time PCR.
Results: There was a statistically significant higher expression levels 
of CDR1, FLU1, ADH1 and DDR48 in resistant and susceptible dose 
dependent isolates than in susceptible isolates (P = 0.009, 0.008, 
0.01, 0.014 respectively). Strong positive correlations were observed 
between the expression levels of each of ADH1and DDR4 with azole 
resistance genes CDR1 and FLU1 [(rs) = 0.945, 0.815, respectively; 
P < 0.001; Spearman’s (rs) = 0.852 and 0.76, respectively; P < 0.001].
Conclusion: This is the first study that showed positive correlation 
between DDR48 and azole resistance genes. It has also indicated that 
ADH1 and DDR48 are associated with the resistance mechanisms of 
C. albicans to fluconazole. Identification of new drugs that target the 
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Introduction
Candida albicans is a human fungal pathogen that 
causes serious infections in immunocompromised 
population [1]. In hospitalized patients, this organism 
can disseminate hematogenously and infect virtually 
all organs [2]. Fluconazole and other azoles enter 
C. albicans cells by facilitated diffusion [3]. These 
antifungal drugs inhibit cytochrome P450 enzymes: 
lanosterol demethylase, a key enzyme in ergosterol 
biosynthesis [4], and C-22 sterol desaturase [5].
C. albicans is becoming increasingly resistant to azole 
antifungal agents, particularly fluconazole, a prob-
lem of growing importance due to the widespread 
use of a limited number of antifungal agents, par-
ticularly azoles [6, 7]. Various mechanisms can lead 
to the acquired resistance of Candida spp. to azole 
drugs, and most involve the induction of the efflux 
pumps encoded by CDR (Candida Drug Resistance) 
or MDR (Multiple Drug Resistance) genes, or the 
over-expression or acquisition of point mutations 
in the gene encoding the target enzyme lanosterol 
demethylase [8]. Over-expression of drug-efflux 
pumps Cdr1, Cdr2 and Mdr1 has been linked to 
fluconazole resistance [9].
Multidrug efflux transporters of the ABC (ATP-bind-
ing cassette) superfamily and of the   Major Facili-
tator Superfamily (MFS) play a key role in the low 
level of accumulation of azoles in the yeast cell [10]. 
The ABC transporter superfamily, including Cdr1 
and Cdr2, are membrane proteins that have two 
membrane-spanning domains and two nucleotide-
binding domains that utilize ATP to drive substrates 
across the membrane [11]. CDR1 and CDR2 genes 
have been shown to be upregulated in resistant 
strains, leading to an enhanced efflux of the drug 
[10] and hence leading to resistance to multiple 
azoles [12, 13]. Cross-resistance between flucon-
azole and other azoles has been reported [14-16], 
the mechanistic basis for this cross-resistance most 
often involves the upregulation of genes encoding 
the CDR pumps that act as ATP-binding cassette 
efflux transporters [13, 17, 18].
On the other hand, MFS drug pumps, including 
Mdr1 and Flu1, have no nucleotide-binding domain 
but instead use the proton motive force of the 
membrane as an energy source [11]. Both MDR1 
and FLU1 genes were over-expressed specifically in 
fluconazole-resistant C. albicans isolates. Disruption 
of FLU1 gene in C. albicans mutants with deletions 
in multidrug efflux transporter genes, including 
CDR1, CDR2 and MDR1, resulted in enhanced sus-
ceptibility to several azole derivatives, indicating the 
contribution of FLU1 in azole resistance [19].
The Adh1p (alcohol dehydrogenase protein) which 
is encoded by the ADH1 gene, plays an important 
role in intracellular energy metabolism [20], as the 
most critical mechanism governing drug resistance 
proteins encoded by these genes will help in eradication of fluconazole 
resistant C. albicans in infection.
Keywords: fluconazole resistance, C. albicans, ADH1, DDR48, CDR1, 
FLU1genes.
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in C. albicans entails the Cdr1p and Cdr2p efflux 
pump proteins, the functionality of which depends 
on energy metabolism [19, 21].
Another gene (DDR48) acts as cell stress gene that 
is involved in combating the effects of nitric ox-
ide and in DNA repair [22]. A study reported that 
DDR48 is upregulated in azole resistant C. albicans 
than in the sensitive isolates [23]. The relationship 
between the expression of ADH1 and DDR48 with 
drug resistance in C. albicans requires further re-
search. Understanding the resistance mechanisms 
and the associated drug resistance genes will help 
in the development of new antifungal agents that 
can reverse drug resistance.
The aim of this study is to investigate the expression 
of ADH1 and DDR48 genes in fluconazole resistant 
C. albicans, and to assess the correlation between 
the expression levels of these genes and the expres-
sion of the azole resistance genes CDR1 and FLU1.
Materials and Methods
Sample collection
This study involved 25 C. albicans clinical isolates. 
Twenty strains were isolated from patients with 
vulvovaginal candidiasis and five strains were iso-
lated from patients with respiratory infections. The 
isolates were collected from patients attending the 
outpatient clinics of Gynecology and Obstetrics de-
partment and patients admitted at Chest depart-
ment in Kasr Al-Aini Hospitals, Cairo University, 
Egypt.  All laboratory tests were carried out in the 
department of Medical Microbiology and Immunol-
ogy, and the department of Biochemistry, Faculty of 
Medicine, Cairo University during the period from 
June 2013 to August 2014. The study protocol was 
approved by the Scientific Ethical Committee at Cai-
ro University Hospitals and informed consent was 
obtained from each patient. All C. albicans isolates 
were identified by germ tube test, culture on Chro-
mID Candida (Biomerieux, France) and by API C20 
identification kit (Biomerieux, France).
Fluconazole disk diffusion susceptibility 
testing
Fresh subcultures of C. albicans isolates were pre-
pared on SDA (Sabouraud dextrose agar). Flucon-
azole susceptibility was tested by using 25-ug fluco-
nazole disks (Biorad, USA) on Mueller-Hinton agar 
supplemented with 2% glucose and 0.5mg/L meth-
ylene blue inoculated with 0.5 McFarland standard 
of an inoculum prepared in sterile 0.9% NaCl [24]. 
The zone diameter was measured after 24 hours. 
Isolates with zone diameter of ≥19 mm were con-
sidered susceptible, those with zone diameter of 15 
to 18mm were considered susceptible dose-depen-
dent, and those with zone diameter ≤14 mm were 
considered resistant [24, 25].
Minimum inhibitory concentration (MIC) 
of fluconazole
C. albicans isolates were subcultured on SDA and 
an inoculum was prepared in sterile 0.9% NaCl, ad-
justing the cell density to 0.5 McFarland standard. 
The MIC of fluconazole was determined by E-test 
(AB BIODISK,Solna, Sweden) using Muller Hinton 
agar supplemented with 2% glucose and 0.5 mg/L 
methylene blue [24]. The MICs were read after 24 
hours. Susceptible, susceptible dose-dependent and 
resistant isolates were defined by MICs of ≤8 mg/L, 
16 to 32 mg/L and  ≥64 mg/L respectively [24, 25].
Total RNA isolation 
C. albicans isolates were grown overnight at 37°C 
on SDA. Three to four colonies were suspended in 
phosphate buffer saline. Total RNA was isolated with 
RNeasy Mini Kit (Qiagen, USA) according to the man-
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ufacturer’s protocol and further analyzed for quantity 
and quality using Beckman dual spectrophotometer 
(USA). The OD260 and OD280 values were mea-
sured, and the ratios were found to be 1.8–2.0. The 
RNA integrity was assessed by RT-PCR measurement 
of CaYST1- mRNA (C. albicans housekeeping gene) 
gene expression as the quality control.
Real Time PCR for quantitative expression 
of ADH1, CDR1, DDR48 and FLU1 genes
The mRNA expression level was measured by qRT–
PCR (quantitative reverse transcription polymerase 
chain reaction). Briefly, 1000 ng of the total RNA 
from each sample were used for cDNA synthesis 
by reverse transcription using High capacity cDNA 
Reverse Transcriptase kit (Applied Biosystem, USA). 
The cDNA was subsequently amplified with the Syb-
er Green I PCR Master Kit (Fermentas, Germany) us-
ing an Applied Biosystem with software version 3.1 
(StepOne™, USA) as follows: 10 minutes at 950C 
for enzyme activation followed by 40 cycles of 15 
seconds at 950C, 20 seconds at 550C and 30 sec-
ond at 720C for the amplification step. We used 
1μM of both primers specific for each target gene. 
The threshold cycle (Ct) value of CaYST1 was sub-
tracted from that of the gene of interest to obtain 
a ΔCT value. The strain with the lowest ΔCT value 
for ADH1 was used as the baseline control strain, 
and the expression levels of the other strains were 
quantified relative to that of the control strain. Fi-
nally, RQ (relative quantity) expression level for each 
target gene was assessed relative to the calibrator 
and was expressed as 2−ΔΔCT. Primers sequences 
specific for each target gene are demonstrated in 
table 1.
Statistical Analysis
Data were analyzed using SPSS version 16. The re-
sults were expressed as means ± standard deviation 
(SD). The relative mRNA expression levels of ADH1, 
CDR1, FLU1 and DDR48 in the susceptible and re-
sistant isolates were compared using the indepen-
dent samples t test, Kruskal Wallis H test was used 
to compare the relative mRNA expression levels of 
ADH1, CDR1, FLU1 and DDR48 in the susceptible, 
susceptible dose dependent and resistant isolates. 
Spearman’s rho (rs) was used for the analysis of 
correlation between the mRNA expression levels of 
the four studied genes. Statistical significance was 
defined at P ≤ 0.05.
Table 1. Sequences of the gene-specific primers for amplification of the studied genes
Gene Primer sequence  5’-3’ Gene bank accession number
ADH1
5’- TGT CTG GTT ACA CTC ACG ATG G -3’
5’- GCA TCG AAA ACT GGA GCA GT -3’
XM_002420714.1
CDR1
5’- CTT AGT CAA ACC ACT GGA TCG -3’
5’- CCA AAA GTG ATG AAA AGG C -3’
XM_718116.1
FLU1
5’- TGT TGC CTT TGA TGG TCC CG -3’
5’- ACC GAT AAG GCA GCA AGA CC -3’
XM_715807.1
DDR48
5’- TTT CGG TTT CGG TAA AGA CG -3’
5’- TGA GTC GGT CTT GGA GGA AC -3’
XM_709160.1
CaYST1
5’- AAGTATTTGGGAGAAGGGA-AAGGG -3’
5’- AAAATGGGCATTAAGGA-AAAGAGC -3’
AJ251858.1
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Results
Fluconazole susceptibility of the  
C. albicans isolates
Fluconazole susceptibility testing revealed that 19 
out 25 isolates were susceptible to fluconazole by 
both disk diffusion method and E-test (zone diam-
eter ≥19; MIC≤8 mg/L), and one isolate was resis-
tant by both tests (zone diameter ≤14; MICs ≥64 
mg/L). The remaining 5 isolates showed discrepancy 
between disk diffusion and E test results, they were 
fluconazole resistant by disk diffusion, however by 
the E test, 2 of them were susceptible and 3 were 
susceptible dose-dependent (MIC =24 mg/L). Those 
5 isolates had high expression levels of CDR1 and 
FLU1 azole resistance genes as well as ADH1 and 
DDR48 genes.
Expression of the studied genes among 
fluconazole susceptible and resistant  
C. albicans isolates
Both the results of the disk diffusion, fluconazole 
resistant C. albicans isolates had significantly higher 
expression levels of ADH1, CDR1, FLU1 and DDR48 
genes than fluconazole susceptible C albicans iso-
lates. Table 2 shows the means, standard devia-
tions and P-values of the expression levels of the 
four studied genes among fluconazole resistant and 
susceptible Candida albicans isolates.
Comparing the expression levels of the studied 
genes among C. albicans isolates based on the E-
test results by Kruskal-Wallis H test revealed statis-
tically significant higher expression levels of CDR1, 
FLU1, ADH1 and DDR48 in susceptible dose depen-
dent and resistant isolates compared to susceptible 
ones, data are shown in table 3.
Correlation between expression of ADH1 
and DDR48 with azole resistance genes
There were strong positive correlations among all 
25 clinical C. albicans isolates between the relative 
mRNA expression levels of ADH1 and the azole re-
sistance genes CDR1 and FLU1 (rs) = 0.945, 0.815, 
respectively; P < 0.001) (Table 4).
Strong positive correlations were also observed be-
tween the relative mRNA expression levels of DDR48 
and each of CDR1 and FLU1 (rs) = 0.852 and 0.76, 
respectively; P < 0.001) (Table 4).
Table 2. Expression levels of the four studied genes among fluconazole resistant and fluconazole suscep-
tible C. albicans isolates
Fluconazole susceptible
n=19
Fluconazole Resistant  
n=6 P-value
Mean SD Mean SD
ADH1 3.32 1.7 12.11 2.0 <0.001
CDR1 2.28 1.3 10.34 2.09 <0.001
FLU1 2.09 1.14 7.93 0.89 <0.001
DDR48 2.71 1.19 8.4 3.36 0.008
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Discussion
Fluconazole susceptibility of C. albicans 
isolates
Nineteen C. albicans isolates were fluconazole sus-
ceptible and one isolate was resistant by both disk 
diffusion and the E-test. The remaining five isolates 
were found resistant by disk diffusion, susceptible 
or susceptible dose-dependent by the E-test. These 
5 isolates had high expression levels of azole resis-
tance CDR1, FLU1 genes as well as with ADH1 and 
DDR48 genes. 
Previous studies reported discrepancy between flu-
conazole disk diffusion and E-test, although Torres 
and colleagues (2009) reported a positive correla-
tion between disk diffusion method and the E-test. 
They observed that one Candida isolate was resis-
tant to fluconazole by disk diffusion but susceptible 
Table 3.  Comparing the expression levels of the four studied genes among C. albicans isolates based on 
the E-test results
Fluconazole E-test N Mean Rank P-value
CDR1
Susceptible 21 11.05 0.009
Susceptible dose dependent 3 22.67
Resistant 1 25.00
FLU1
Susceptible 21 11.00 0.008
Susceptible dose dependent 3 23.67
Resistant 1 23.00
ADH1
Susceptible 21 11.05 0.01
Susceptible dose dependent 3 22.67
Resistant 1 25.00
DDR48
Susceptible 21 11.14 0.014
Susceptible dose dependent 3 22.00
Resistant 1 25.00
Table 4.  Correlation of the mRNA expression levels of ADH1 and DDR48 to azole resistance genes CDR1 
and FLU1
Gene Mean±SD
Spearman’s rho (rs)
Correlation Coefficient to ADH1
Spearman’s rho (rs)
Correlation Coefficient to DDR48
5.43±4.20 4.07±3.09
CDR1 4.21±3.81 0.945* 0.852*
FLU1 3.5±2.76 0.815* 0.760*
*P-value < 0.001
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by the E-test [26]. Furthermore, a study by Van-
denbossche and colleagues (2002) reported that 
one  C. tropicalis strain, with MIC>256 mg/L was 
observed to be susceptible by the E-test (MIC = 0.5 
mg/L) using broth macro-dilution method [27]. The 
agreement between the E-test and macro-dilution 
method ranged from 87-100% within two dilutions 
for Candida spp. In general, there was a tendency 
to read the E-test MICs slightly lower than mac-
ro- and micro-dilution methods [27-29]. It is worth 
mentioning that fluconazole susceptibility testing of 
C. albicans using the E-test technique is difficult to 
interpret due to the fact that scattered inner colo-
nies can make the inhibition zones difficult to read, 
a phenomenon called trailing endpoints [28-31]. 
Presence of trailing in Candida isolates, although 
susceptible to fluconazole, means express the same 
molecular mechanisms as SDD and resistant isolates 
following fluconazole exposure [32]. Therefore, mo-
lecular tools should become the gold standard for 
the identification of Candida drug resistance. In-
terestingly, the five isolates, that were resistant by 
disk diffusion and susceptible or susceptible dose-
dependent by the E-test, had high expression levels 
for tested azole resistance genes (CDR1, FLU1, ADH1 
and DDR48).
Expression of the studied genes among 
fluconazole susceptible and resistant  
C. albicans isolates
The present study showed significantly higher ex-
pression levels of CDR1, FLU1, ADH1 and DDR48 
genes in fluconazole resistant than in fluconazole 
susceptible C. albicans isolates. These results are in 
concordance with a study by Guo et al. (2013) who 
reported that ADH1, CDR1 and FLU1 were highly 
expressed in the resistant C. albicans isolated from 
patients with vulvovaginal candidiasis than in sus-
ceptible dose-dependent isolates. They also report-
ed a significant positive correlation between the 
expression of ADH1 and the MICs of fluconazole 
[33]. On the other hand, Siikala et al. (2011) demon-
strated a negative correlation between the relative 
expressions of ADH1 and each of CDR1 and CDR2 
in C. albicans isolated from autoimmune polyen-
docrinopathy–candidosis–ectodermal dystrophy pa-
tients. They also observed no correlation between 
the expression levels of ADH1 and the MICs of 
fluconazole. They conferred these results to meta-
bolic changes in the isolates. For example: catabolite 
repression leading to ADH repression which could 
induce CDRs in their patients [34].
Correlation between ADH1 and the azole 
resistance genes expression
In this study, there were strong positive correla-
tions between the relative mRNA expression levels 
of ADH1 and the azole resistance genes CDR1 and 
FLU1 (Spearman’s (rs) = 0.945, 0.815, respectively; 
P < 0.001). Similarly, Guo et al. (2013) reported that 
the expression of the ADH1 gene was positively cor-
related with the expression of the azole resistance-
associated genes CDR1 and FLU1, indicating that 
high ADH1 mRNA expression is closely correlated 
to drug resistance in C. albicans [33].
Adh1p is involved in glycolysis, which is the major 
metabolic reaction under anoxic conditions in yeast, 
and is responsible for most of the alcohol dehydro-
genase activity in yeast [35]. The high expression 
of the ADH1 gene is likely plays a role in promot-
ing drug resistance in C. albicans. Elevated ADH1 
gene expression may signify the activation of the 
glycolysis pathway, which can result in enhanced 
ATP generation. Thus, more energy is produced for 
the drug efflux pump located in the C. albicans cell 
membrane, leading to the export of azole drugs and 
a decrease in the intracellular accumulation of these 
drugs, and results in drug resistance [33]. Further-
more, the Adh1p was found to be upregulated at 
the protein level in fluconazole resistant C. albicans 
[36, 37].
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Correlation between DDR48 gene 
expression and azole-resistance genes
There were also strong positive correlations between 
the relative mRNA expression levels of DDR48 and 
each of CDR1 and FLU1 (Spearman’s (rs) = 0.852 and 
0.76, respectively; P < 0.001). Barker et al. (2004) 
reported that the expression of the cell stress gene 
DDR48, a member of a set of genes that displays 
increased transcription in response to DNA lesions, 
heat-shock stress [38], and in C. albicans biofilms 
[39], was up-regulated by 7.4 fold in the azole re-
sistant C. albicans isolate than in the sensitive one 
[23]. Cleary et al. (2012) demonstrated a role for 
DDR48 in sensing or responding to environmental 
nutritional conditions, they concluded that this pro-
tein has an important influence on pathogenesis 
[40]. Furthermore, DDR48 mutant strain generated 
in a study by Dib et al. (2008) was susceptible in 
a dose-dependent manner to fluconazole and itra-
conazole compared with the resistant parent strain 
that possesses DDR48 gene [41]. Previous data also 
showed that exposure to fluconazole and itracon-
azole led to increased expression of DDR48 RNA 
[42]. It is worth pointing out that the importance of 
DDR48 for filamentation, stress response and bio-
film formation highlights its role in virulence and 
makes it a prime target for antifungal drug design 
[41]. Interestingly, our results indicate that the cor-
relation of ADH1 was higher than that of DDR48 to 
azole resistance genes, suggesting that the ADH1 
gene has more crucial role and is more reliable in 
detecting azole resistance in C. albicans.
In conclusion, the mRNA expression levels of ADH1 
and DDR48 had strong positive correlation with 
the expression levels of CDR1 and FLU1 azole re-
sistance genes. Furthermore, ADH1 and DDR48 
expression levels were significantly higher in fluco-
nazole resistant than in fluconazole susceptible C. 
albicans clinical isolates. These results indicate that 
these genes have an important role in the resistance 
mechanisms of C. albicans to fluconazole and prob-
ably to other azoles. Identification of new drugs 
that target the proteins encoded by these genes 
will help in eradication of fluconazole resistant C. 
albicans during infection. To our knowledge, this is 
the first study that investigates the association be-
tween DDR48 and azole resistance genes. Further 
research is required to clarify the role of DDR48 in 
drug resistance mechanisms. However, the role of 
ADH1 seems to be more crucial in azole resistance 
in C. albicans.
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